In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please cancel claims 13, 15-17, and 22-24 without prejudice to their presentation in another application, amend claims 12-14 and 21, and add new claims 29-32 as follows:

1-11. (canceled).

12. (currently amended) A ~~vaccine~~ composition comprising a peptide ~~sequence~~ comprising ~~the N-terminal portion of the angiotensin-II type-1 receptor defined by~~ the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1), in which the peptide is conjugated to a carrier protein ~~or a fragment thereof~~.

13. (canceled).

14. (currently amended) A method of treating cancer ~~comprising~~ comprising:

administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide;

wherein the peptide comprises ~~an N-terminal portion of an angiotensin-II type-1 receptor comprising~~ the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1)~~, a conservative mutant thereof, or an active fragment thereof comprising at least five amino acid residues~~.

15-17. (canceled).

18. (previously presented) The method of claim 14 wherein the monoclonal antibody is humanized.

19. (previously presented) The method of claim 14 wherein the monoclonal antibody is 6313/G2 produced by the hybridoma cell line designated by accession number 93072117.

20. (previously presented) The method of claim 14 wherein the cancer is prostate cancer or breast cancer.

21. (currently amended) A method of treating a disease or condition associated with vascular smooth muscle cell proliferation ~~comprising~~ comprising:

administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide;

wherein the peptide comprises ~~an N-terminal portion of an angiotensin-II type-1 receptor comprising~~ the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1)~~, a conservative mutant thereof, or an active fragment thereof comprising at least five amino acid residues~~.

22-24. (canceled).

25. (previously presented) The method of claim 21 wherein the monoclonal antibody is humanized.

26. (previously presented) The method of claim 21 wherein the monoclonal antibody is 6313/G2 produced by the hybridoma cell line designated by accession number 93072117.

27. (previously presented) The method of claim 21 wherein the disease or condition is atherosclerosis.

28. (previously presented) The composition of claim 12 further comprising an adjuvant.

29. (new) A composition comprising a peptide comprising up to 45 amino acids, and comprising the sequence EDGIKRIQDD (SEQ ID NO:2).

30. (new) The composition of claim 29 in which the peptide is conjugated to a carrier protein.

31. (new) The method of claim 14 wherein the antibody fragment is a Fab, $F(ab')_2$, Fv, or scFv fragment.

32. (new) The method of claim 21 wherein the antibody fragment is a Fab, $F(ab')_2$, Fv, or scFv fragment.